I had hoped that we add to our ocular presentation.
Tellingly, the CNS presentation was only shared during conference as this is more market and competition sensitive in regard to other companies.
Dual approach in Phelan McDermid Syndrome very impressive and showing depth of multiple pathways., possibly applicable to other programs.
Financial developments around the corner, possibly securing CEO's 18 mil share issuance as shareholders would be supportive on the heels of such news..
lots to look forward to in the next 6 months.
all IMO
Ann: Phelan-McDermid Syndrome & CNS platform presentation, page-2
Add PYC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
10.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $489.9M | |||
| Open | High | Low | Value | Volume |
| 10.5¢ | 11.0¢ | 10.0¢ | $392.3K | 3.706M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 18 | 1506182 | 10.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 11.0¢ | 1714856 | 9 |
View Market Depth
| Last trade - 16.10pm 22/05/2024 (20 minute delay) ? |
|
|||||
|
Last
10.5¢ |
Change
0.000 ( 4.17 %) |
||||
| Open | High | Low | Volume | ||
| 10.8¢ | 11.0¢ | 10.5¢ | 1029511 | ||
| Last updated 15.58pm 22/05/2024 ? | |||||
| PYC (ASX) Chart |